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Abstract
Huntington’s disease is a fatal neurodegenerative condition caused by a CAG repeat
expansion in the huntingtin gene. The peripheral innate immune system is dysregulated in
Huntington’s disease and may contribute to its pathogenesis. However, it is not clear
whether or to what extent the adaptive immune system is also involved. Here, we carry out
the first comprehensive investigation of human ex vivo T lymphocytes in Huntington’s dis-
ease, focusing on the frequency of a range of T lymphocyte subsets, as well as analysis of
proliferation, cytokine production and gene transcription. In contrast to the innate immune
system, the intrinsic phenotype of T lymphocytes does not appear to be affected by the
presence of mutant huntingtin, with Huntington’s disease T lymphocytes exhibiting no sig-
nificant functional differences compared to control cells. The transcriptional profile of T lym-
phocytes also does not appear to be significantly affected, suggesting that peripheral
immune dysfunction in Huntington’s disease is likely to be mediated primarily by the innate
rather than the adaptive immune system. This study increases our understanding of the
effects of Huntington’s disease on peripheral tissues, while further demonstrating the differ-
ential effects of the mutant protein on different but related cell types. Finally, this study sug-
gests that the potential use of novel therapeutics aimed at modulating the Huntington’s
disease innate immune system should not be extended to include the adaptive immune
system.
Introduction
Huntington’s disease (HD) is a fatal, autosomal dominant neurodegenerative condition caused
by a CAG repeat expansion in exon 1 of the huntingtin (HTT) gene on chromosome 4 [1]. A
sequence of 40 or more CAG repeats is fully penetrant and results in the disease. Patients are
affected by a combination of symptoms, including movement disorders and cognitive
impairment, and the disease is uniformly fatal 15–20 years after its onset [2]. No treatments are
currently available to slow the progression of the disease. Disease pathology has been
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traditionally considered to be confined to the central nervous system (CNS), but in recent years
it has become apparent that HD is a disease of the whole body, with patients being affected by
peripheral pathology including skeletal muscle wasting and testicular atrophy [3]. Indeed, the
mutant (m)HTT protein has been found to be expressed in all cells and tissues that have been
studied [4].
Immune system dysfunction is a recognised part of HD pathogenesis, both in the CNS in
the form of microglial activation [5], and the periphery where increased circulating levels of
pro-inflammatory cytokines [6] and chemokines [7] are detectable in the blood many years
before the onset of disease. The peripheral immune system may act as a modifier of disease
progression, with the administration of immunomodulatory drugs improving the phenotype of
HD mouse models [8, 9]. Recent work attempting to identify the cause(s) of this dysfunction
has focused on the cells of the innate immune system. Indeed, HD myeloid cells are hyper-
reactive in response to lipopolysaccharide (LPS), producing significantly elevated levels of pro-
inflammatory cytokines such as IL-6 and TNFα [10]. This is due at least in part to a direct
interaction of the mHTT protein with IKK, the key kinase in the NFκB pathway, and these
changes are reversible following HTT lowering with small interfering RNA (siRNA). HD mye-
loid cells have also been shown to exhibit functional deficits when migrating to chemotactic sti-
muli [11] and phagocytosing fluorescent beads [12].
However, very little is known about the adaptive immune system in HD. In contrast to the
innate immune system, which provides an immediate generic response to a wide range of
pathogens, the adaptive immune system generates a highly specific secondary response that
is also known as immunological memory. The adaptive immune system is largely mediated
by T lymphocytes, which produce cytokines to enhance or suppress the activity of other
immune cells, and B lymphocytes that generate antibodies following exposure to specific
pathogens. T lymphocytes are further categorised as a number of subsets, including CD4+
helper T lymphocytes (including Th1 and Th2 lymphocytes) and CD8
+ cytotoxic T lympho-
cytes. There is much interplay between the innate and adaptive immune systems, which is
required for both to function effectively [13, 14]. For example, professional antigen present-
ing cells such as dendritic cells and macrophages display exogenous antigens on major histo-
compatibility complex (MHC) class II molecules in order to activate CD4+ helper T
lymphocytes, which respond by differentiating and producing a range of cytokines that direct
both the innate and adaptive immune responses [15]. It is not clear currently whether such
interplay is affected in HD, or whether HD immune dysfunction is universal or restricted to
specific cell types.
Previous work has shown that mHTT is expressed in T lymphocytes, and levels of the
mutant protein in this cell type have been found to correlate with disease burden scores and
caudate atrophy [16]. Levels of the signature Th2 cytokine IL-4 are also significantly elevated in
the plasma of HD patients [6], suggesting that mHTT may have an adverse effect on T lympho-
cyte function. In this study we carry out the first comprehensive investigation of human ex vivo
HD T lymphocytes, with a focus on CD4+ helper T lymphocytes (one of the main effector cells
of the adaptive immune system). The frequency of a range of T lymphocyte subsets was mea-
sured by flow cytometry, before the intrinsic function of HD T lymphocytes was examined
using proliferation assays and cytokine profiling. Finally, the expression levels of 84 key T lym-
phocyte related genes were investigated using quantitative polymerase chain reaction (qPCR)
arrays. These data have important implications for potential future therapeutic strategies
aimed at modulating the immune system in HD.
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Materials and Methods
Collection and classification of human samples
All human experiments were performed in accordance with the Declaration of Helsinki and
approved by the University College London (UCL)/UCL Hospitals Joint Research Ethics Com-
mittee. Blood samples were donated by genetically-diagnosed HD patients and control sub-
jects, and all subjects provided informed written consent. HD subjects were classified on the
basis of their total functional capacity (TFC) score; only manifest subjects with early or moder-
ate stage disease (TFC 13–3) were included in the study. The HD and control groups were age-
matched for all experiments (S1 Table). Subjects with inflammatory or infective conditions
were excluded from the study.
Isolation of peripheral blood mononuclear cells
Peripheral blood mononuclear cells (PBMCs) were isolated from human peripheral blood sam-
ples by density centrifugation. Twenty five ml peripheral blood was layered on top of 20 ml
Histopaque-1077 (Sigma-Aldrich) in 50 ml tubes, before centrifuging at 400 xg for 30 min with
minimum deceleration. The PBMC layer was then transferred to a fresh tube using a Pasteur
pipette.
Cell culture and stimulation
Cells were cultured in RPMI 1640 culture medium supplemented with 10% foetal bovine
serum (FBS), 2 mM L-glutamine, 50 U/ml penicillin and 50 μg/ml streptomycin (Invitrogen).
CD3 stimulation was carried out using plate-bound functional grade anti-human CD3 anti-
body (eBioscience). Five μg/ml antibody diluted in PBS was added to each culture well before
incubating at 4°C for 24 h. The wells were washed with PBS to remove any unbound antibody,
before 2 μg/ml functional grade anti-human CD28 antibody (eBioscience) was added to the
culture medium to provide appropriate co-stimulation. PHA-P stimulation was carried out by
adding 10 μg/ml PHA-P (Sigma-Aldrich) directly to the culture medium.
Flow cytometry
Amaximum of 1 x 106 cells were transferred into a V-bottomed 96 well plate and centrifuged
at 400 xg for 5 min. Staining of cell surface markers was carried out by resuspending the cells
in 50 μl antibody suitably diluted in FACS buffer (PBS with 1% FBS and 0.02% sodium azide).
A full list of antibodies used is included in S2 Table. Cells were stained for 60 min on a shaker
at 4°C in the dark before washing in 200 μl FACS buffer by centrifuging at 400 xg for 5 min.
Cells were then fixed using 4% paraformaldehyde in PBS for 10 min. After fixing the cells were
washed again and transferred to FACS tubes for analysis. Flow cytometry was carried out using
a MACSQuant flow cytometer (Miltenyi Biotech) with MACSQuantify software. Data analysis
was performed using FlowJo 7.2.5 (Tree Star) software. Non-stained and single colour stained
controls were always performed.
T lymphocyte proliferation assays
Cell staining for proliferation assays was carried out using carboxyfluorescein succinimidyl
ester (CFSE). After isolation PBMCs were counted using a Neubauer counting chamber and
resuspended at 1 x 107 cells per ml of PBS with 5% FBS to buffer against the toxic effects of
CFSE. CFSE was added to the suspension for a final concentration of 5 μM, before the sample
was mixed vigorously and incubated for 10 min at room temperature in the dark. Labelling was
stopped by adding cold RPMI medium with 10% FBS and incubating on ice for 5 min. After
Adaptive Immunity in Huntington’s Disease
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labelling the cells were seeded at 5 x 105 cells per well in 48 well plates, and were either left
unstimulated or stimulated with anti-CD3 and anti-CD28 antibodies or PHA-P as described
above. Unstained cells were also seeded to provide appropriate controls for flow cytometry.
Cells were harvested after 72, 96 and 120 h and stained with Fixable Viability Dye 660
(eBioscience) according to the manufacturer’s instructions. Cells were then stained and ana-
lysed by flow cytometry as described above.
Magnetic cell sorting
CD4+ T lymphocytes were isolated by magnetic cell sorting. PBMCs were counted using a Neu-
bauer counting chamber before being resuspended in 10 μl anti-human CD4 beads (Miltenyi
Biotec) and 90 μl MACS buffer (PBS with 1% BSA and 2 mM EDTA) per 107 cells. After 15
min incubation at 4°C the samples were centrifuged at 400 xg for 5 min before being resus-
pended in 500 μl MACS buffer. Magnetic cell sorting was carried out by placing MACS col-
umns (Miltenyi Biotec) in a magnetic field and adding each cell suspension to an individual
column. The columns were washed with MACS buffer before magnetically labelled CD4+ T
lymphocytes were eluted by taking the columns out of the magnetic field and plunging MACS
buffer through the column. On average, the sorted cell populations contained 85–95% CD4+
cells.
Cytokine profiling
CD4+ T lymphocytes were isolated as described above, before being seeded at 1 x 105 cells per
well in 96 well plates. Cells were either left unstimulated or stimulated with anti-CD3 and anti-
CD28 antibodies for 48 h as described above. After 48 h the supernatants were collected and
analysed using V-PLEX Pro-inflammatory Panel 1 (human) and V-PLEX Human IL-5 kits
(Meso Scale Discovery) according to the manufacturer’s instructions. Data analysis was carried
out using Discovery Workbench 4.0 (Meso Scale Discovery), before cytokine values were nor-
malised to the total protein content of the well. Protein values were measured using the Pierce
bicinchoninic acid (BCA) protein assay kit (Thermo Scientific) according to the manufactur-
er’s instructions.
Quantitative polymerase chain reaction arrays
CD4+ T lymphocytes were isolated as described above, prior to seeding at 5 x 106 cells per dish
in 60 mm dishes. Cells were either left unstimulated or stimulated with anti-CD3 and anti-
CD28 antibodies for 8 h as described above. After 8 h the cells were harvested and RNA was
extracted using the RNeasy Mini Kit (Qiagen) according to the manufacturer’s instructions.
The concentration of each sample was measured using an ND-1000 Spectrophotometer
(NanoDrop), before RNA integrity was assessed using 2100 Bioanalyser NanoChips (Agilent).
Only samples with non-degraded RNA were used for the quantitative polymerase chain reac-
tion (qPCR) arrays.
Six hundred ng of RNA from each sample was reverse transcribed using the RT2 First
Strand Kit (Qiagen) and analysed using the Human Th1 and Th2 Responses RT
2 Profiler PCR
Array (SABiosciences) according to the manufacturers’ instructions. SYBR green was used as
the reporter dye while ROX was used as the passive dye. Prior to analysis a consistent threshold
value was set for each sample and any samples showing signs of genomic DNA contamination
were excluded. Data analysis was carried out using the online data analysis tool provided by
the manufacturer (http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php). Genes
with an average Ct value of>35 were excluded from the final results.
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Statistical analysis
Statistical analysis of immune cell subset, proliferation and cytokine profiling data was carried
out using GraphPad Prism 6 (GraphPad), while qPCR array data was analysed using the manu-
facturer’s online tool as outlined above. All experiments were analysed using unpaired two-
tailed Student’s t-tests. Where appropriate post-hoc analysis of multiple t tests was carried out
using a Holm-Šídák correction (alpha = 0.05) for multiple comparisons. All error bars repre-
sent standard error of the mean.
Results
The frequency of T lymphocyte subsets does not differ between HD and
control peripheral blood
It has been demonstrated previously that circulating levels of pro-inflammatory cytokines and
chemokines are elevated in HD plasma [6, 7]. One possible cause of this is a shift in the relative
proportions of different immune cell subtypes, leading to changes in the overall cytokine envi-
ronment being produced. PBMCs were isolated from manifest HD and control blood samples
and stained with antibodies for CD3+ T lymphocytes, CD3+ CD4+ helper T lymphocytes and
CD3+ CD8+ cytotoxic T lymphocytes. Helper T lymphocytes were further investigated using
antibodies for CXCR3+ Th1 lymphocytes and CCR4
+ Th2 lymphocytes. No significant differ-
ences were detected for any of the T lymphocyte subtypes measured as a percentage of the HD
and control PBMC populations (Fig 1, gating schematic in S1 Fig). This is consistent with a
recent study that showed that the frequency of CD3+ T lymphocytes is not altered in the spleen
and bone marrow of R6/2 and wild-type mice [12]. The activation levels of CD4+ and CD8+ T
lymphocytes were also assessed by CD62Llow expression. Again, no significant differences were
seen between the HD and control PBMC populations (Fig 2).
T lymphocyte proliferation in response to stimuli is not impaired in HD
compared to control
HDmyeloid cells display functional deficits when migrating to chemotactic stimuli and phago-
cytosing fluorescent beads [11, 12]. Here, we sought to investigate whether HD T lymphocytes
exhibit similar functional abnormalities. The ability of lymphocytes to rapidly proliferate in
response to a stimulus is a key feature of the adaptive immune system. PBMCs were isolated
from manifest HD and control peripheral blood samples before being stained with the intracel-
lular dye CFSE. CFSE is a highly stable fluorescent dye that is evenly divided between the two
daughter cells produced when a cell divides. This allows the tracking of multiple cell divisions
in vitro by flow cytometry as a sequential halving of fluorescence intensity [17, 18]. After stain-
ing, the PBMC populations were either left unstimulated or stimulated with either anti-CD3
and anti-CD28 antibodies or PHA-P. This enabled us test the cells’ response to antigenic and
mitogenic stimuli, respectively. Cultures were harvested after 72, 96 and 120 h to build up a
broad profile of the proliferative response.
The proliferative response of three T lymphocyte populations (all CD3+, CD3+ CD4+ and
CD3+ CD8+ cells, gating schematic in S2 Fig) was analysed using a range of statistics as out-
lined by Roederer [19]. No significant differences were seen in the percentage of CD3+ T lym-
phocytes from the initial culture that entered cell division (percentage divided) for any of the
experimental conditions or time points (Fig 3). Similarly, no significant differences were seen
in the average number of divisions each dividing CD3+ T lymphocyte underwent (proliferation
index) (Fig 4). Similar results were obtained when the CD4+ and CD8+ subtypes were analysed,
with no significant differences being observed for any of the experimental conditions or time
Adaptive Immunity in Huntington’s Disease
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points (S3 and S4 Tables). Additional analysis was carried out to determine the average number
of divisions all cells in culture underwent (division index) (S5 Table), as well as the percentage
of cells in the final culture which had divided at least once (fraction diluted) (S6 Table). Again,
no significant differences were seen between the HD and control samples. These results dem-
onstrate that proliferation in response to a stimulus is not impaired in any of the major T lym-
phocyte populations in HD.
Cytokine production by ex vivo HD helper T lymphocytes is not altered
compared to controls
HDmonocytes and macrophages are hyper-reactive and produce significantly elevated levels
of IL-6 and TNFα following LPS stimulation compared to control cells [10]. Here, we investi-
gated whether HD T lymphocytes have a similarly hyper-reactive phenotype in response to a
stimulus. CD4+ helper T lymphocytes were isolated from manifest HD and control peripheral
blood samples and stimulated with anti-CD3 and anti-CD28 antibodies for 48 h, after which
Fig 1. The frequency of T lymphocyte subsets does not differ between HD and control peripheral
blood. The frequencies of a range of T lymphocyte subsets in the isolated PBMC populations were
measured by flow cytometry using antibodies to CD3+ T lymphocytes, CD3+ CD4+ helper T lymphocytes and
CD3+ CD8+ cytotoxic T lymphocytes. Within the CD3+ CD4+ helper T lymphocyte population, the Th1 and Th2
subtypes were analysed using antibodies to CXCR3 and CCR4 respectively. No significant differences were
seen between HD and control for any of the cell types that were analysed. Statistical analysis was carried out
using two-tailed unpaired student’s t tests.
doi:10.1371/journal.pone.0141793.g001
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the cell culture supernatants were collected and analysed using multiplex assays. Unstimulated
cells were also seeded in order to investigate baseline cytokine levels.
In contrast with HD myeloid cells, no significant differences were seen in the levels of any of
the eleven cytokines that were measured in the stimulated HD and control samples (Fig 5). A
number of cytokines in the unstimulated samples were below the detection limits of the assay,
but those which were measurable also showed no significant differences between the HD and
control samples (S3 Fig). These results demonstrate that the cytokine profile of HD helper T
lymphocytes is not significantly affected by the presence of mHTT.
The transcriptional profile of HD helper T lymphocytes is not
dysregulated compared to controls
While these experiments have suggested that the intrinsic T lymphocyte phenotype is not
altered between HD and control subjects, it is still possible that there are transcriptional differ-
ences that do not have a detectable effect at the functional level in an ex vivo setting. Transcrip-
tional dysregulation is a key feature of HD pathogenesis [20], whereby the mHTT protein
sequesters transcription factors [21] and binds directly to DNA [22]. Transcriptional changes
have previously been demonstrated in HDmyeloid cells, with reversal of IRAK1, CD40 and
JUN expression differences being achieved following HTT lowering with siRNA [10]. Here, we
sought to investigate whether the mHTT protein has a similar effect on the transcriptional pro-
files of HD T lymphocytes. CD4+ helper T lymphocytes were isolated from manifest HD and
control peripheral blood samples and either left unstimulated or stimulated with anti-CD3 and
anti-CD28 antibodies for 8 h. The messenger RNA (mRNA) expression of eighty four key T
Fig 2. Activation levels of T lymphocyte subsets are not altered between HD and control peripheral blood.Within the previously analysed T
lymphocyte populations (Fig 1), the activation levels of each were measured using CD62Llow expression. No significant differences were seen in the
activation levels of any of the HD populations compared to control. Statistical analysis was carried out using two-tailed unpaired student’s t tests.
doi:10.1371/journal.pone.0141793.g002
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lymphocyte related genes was then measured using the SABiosciences Human Th1 and Th2
Responses RT2 Profiler PCR Array.
We identified two genes which were significantly upregulated (p<0.05) in the unstimulated
HD samples compared to control (TNFSF4, PTGDR2) (Table 1), and three genes which were
significantly upregulated in the stimulated HD samples compared to control (TYK2,
TNFRSF8, STAT6) (Table 2). No genes were found to be significantly downregulated in either
the unstimulated or stimulated HD samples compared to control. However, none of the upre-
gulated genes had a fold change of>1.8 between HD and control, and only two (PTGDR2,
TNFRSF8) had a fold change of>1.5. Furthermore, the expression of signalling molecules
such as MAPK8 (JNK1) and JAK1/2 was not altered in either the unstimulated or stimulated
HD samples (complete data in S7 and S8 Tables). Consistent with the cytokine profiling data,
the mRNA levels of IFNγ, IL-2, IL-5, IL-6, IL-10, IL-13 and TNFα were not altered between
HD and control in either the stimulated or unstimulated samples. IL-4 and IL12B transcript
levels were not detectable in the unstimulated samples, but were similarly unchanged in the
stimulated samples. IL-1β and IL-8 were not included in the list of genes measured by the
Fig 3. The percentage of proliferating CD3+ T lymphocytes is not affected in HD compared to control. PBMCs were stained with CFSE and the
percentage of CD3+ T lymphocytes from the initial culture which divided (A) in the absence of stimulation (B) with 5 μg/ml anti-CD3 and 2 μg/ml anti-CD28
antibody stimulation and (C) with 10 μg/ml PHA-P stimulation was measured after 72, 96 and 120 h by flow cytometry. No significant differences were seen
between HD and control for any of the experimental time points or conditions. Statistical analysis was carried out using two-tailed unpaired student’s t tests
with a Holm-Šídák correction (alpha = 0.05) for multiple comparisons.
doi:10.1371/journal.pone.0141793.g003
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array. The lack of IL-10 expression changes are a further contrast with HDmyeloid cells, as
unstimulated HDmonocytes were found to express significantly more IL-10 mRNA than con-
trols [10]. Taken together, these results suggest that sub-phenotypic transcriptional dysregula-
tion is not a significant phenomenon in HD helper T lymphocytes.
Discussion
Peripheral immune dysfunction is an established feature of HD pathogenesis, with elevated
plasma cytokine and chemokine levels being detectable up to 16 years before the predicted
onset of disease [6, 7]. Recent work has focused on identifying the cause of this dysfunction,
with HD monocytes and macrophages being found to produce significantly increased levels of
pro-inflammatory molecules in a HTT-dependent manner following LPS stimulation [10].
However, this does not preclude other cell types from playing a contributing role in HD
peripheral immune dysfunction. T lymphocytes are vital for adaptive immunity, performing a
wide range of effector and regulatory functions in the body’s defence against pathogens. The
close interplay between T lymphocytes and myeloid cells, in the form of antigen presentation
Fig 4. The number of divisions which proliferating CD3+ T lymphocytes undergo is not affected in HD. PBMCs were stained with the intracellular dye
CFSE and the number of divisions which proliferating CD3+ T lymphocytes underwent (A) in the absence of stimulation (B) with 5 μg/ml anti-CD3 and 2 μg/ml
anti-CD28 antibody stimulation and (C) with 10 μg/ml PHA-P stimulation was measured after 72, 96 and 120 h by flow cytometry. No significant differences
were seen between HD and control for any of the experimental time points or conditions. Statistical analysis was carried out using two-tailed unpaired
student’s t tests with a Holm-Šídák correction (alpha = 0.05) for multiple comparisons.
doi:10.1371/journal.pone.0141793.g004
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and cytokine feedback loops, means that the investigation of T lymphocytes is important in
determining whether HD immune dysfunction is universal or restricted to specific cell types.
Similarly to myeloid cells in HD, T lymphocytes express mHTT, the levels of which have
been found to correlate with disease burden scores and caudate atrophy in HD patients [16].
While the presence of mHTT does not guarantee phenotypic dysfunction, plasma levels of the
signature Th2 cytokine IL-4 are elevated in manifest HD patients [6]. However, the same study
also found that immunoglobulin (Ig) levels were not altered between HD patients and controls,
Fig 5. Cytokine production by stimulated HD helper T lymphocytes is not altered compared to controls. CD4+ helper T lymphocytes were isolated
from HD and control peripheral blood using magnetic cell sorting and stimulated with 5 μg/ml anti-CD3 and 2 μg/ml anti-CD28 antibodies. Supernatants were
collected after 48 h and cytokine profiling was carried out. No significant differences were seen in the levels of any of the cytokines produced by HD and
control CD4+ T lymphocytes after normalisation to total protein levels. Data showmean concentrations ± SEM. Statistical analysis was carried out using two-
tailed unpaired student’s t tests.
doi:10.1371/journal.pone.0141793.g005
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pointing away from any substantial widespread dysregulation of the adaptive immune system.
T lymphocytes were also found not to be enriched in post-mortem HD brain tissue [23], sug-
gesting that they may not play a key role in CNS inflammation in HD. In order to answer the
question of whether the peripheral adaptive immune system is contributing to HD pathogene-
sis, we undertook a comprehensive, multi-faceted approach to investigating whether the intrin-
sic biology of T lymphocytes is affected in HD.
One potential cause of immune dysfunction is a shift in the relative frequencies of immune
cell subsets, resulting in a knock on effect on the overall cytokine and chemokine environment.
Here we show that the proportions of the main T lymphocyte subsets are not altered in HD
and control peripheral blood samples. This is consistent with a previous study showing that the
frequency of CD3+ T lymphocytes is not altered in the spleen and bone marrow of R6/2 and
wild-type mice [12]. Taken together, these studies point away from any widespread changes in
HD immune cell frequencies, and suggest that any immune alterations are likely to be the result
of functional differences and not differences in the relative numbers of different cell types.
Table 1. The top ten gene changes in unstimulated Huntington’s disease helper T lymphocytes com-
pared to controls.
Gene name Fold change P value
TNFSF4 1.471 0.008
PTGDR2 1.788 0.014
GATA3 1.177 0.056
IL18R1 1.336 0.058
IL5 2.245 0.063
LAT 0.893 0.101
IL2RA 1.154 0.102
CSF2 0.490 0.124
JAK1 1.108 0.137
CCR4 1.258 0.183
Data presented as fold change calculated from ΔΔ-CT values, unpaired two-tailed t-test used as statistical
method.
doi:10.1371/journal.pone.0141793.t001
Table 2. The top ten gene changes in stimulated Huntington’s disease helper T lymphocytes com-
pared to controls.
Gene name Fold change p value
TYK2 1.176 0.002
TNFRSF8 1.702 0.013
STAT6 1.231 0.035
TNFSF4 1.756 0.066
JAK1 1.169 0.072
CCR4 1.191 0.118
IL18R1 1.129 0.149
CD27 1.261 0.152
STAT1 0.844 0.162
IL15 0.800 0.184
Cells were stimulated with anti-CD3 and anti-CD28 antibodies for 8 h prior to analysis. Data presented as
fold change calculated from ΔΔ-CT values, unpaired two-tailed t-test used as statistical method.
doi:10.1371/journal.pone.0141793.t002
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Furthermore, we have shown that the activation levels of T lymphocytes as measured by
CD62Llow in HD are no different to controls, suggesting that they do not display significantly
more activation in their normal physiological state.
In addition in their hyper-reactive cytokine profiles, HD myeloid cells have been shown to
be functionally abnormal in tests of migratory and phagocytic capability [11, 12]. Here we
show that HD T lymphocytes do not display similar functional deficits when proliferating in
response to a stimulus. This is the case throughout the proliferative response, and applies to
both the percentage of dividing cells and the number of divisions those cells undergo. In addi-
tion, CD4+ helper T lymphocytes had a similar cytokine profile to controls following antigenic
stimulation. These results suggest that, unlike HDmyeloid cells, HD T lymphocytes do not suf-
fer from any intrinsic functional impairment. One possible explanation for this contrast is the
relative contributions of different intracellular signalling pathways.
It has previously been shown that mHTT directly interacts with IKK, the key kinase in the
NFĸB pathway [24]. This leads to an increased translocation of NFĸB to the nucleus and an
up-regulation of NFĸB related genes [10]. In myeloid cells the NFĸB pathway is vital for the
production of pro-inflammatory cytokines such as IL-6 and TNFα [25], and NFĸB dysfunction
in HD myeloid cells is likely to be a key reason for their hyper-reactive phenotype. While the
NFĸB pathway also plays an important role in T lymphocyte signalling [25], additional tran-
scription factors such as the NFAT and MAPK families are heavily involved in processes such
as cytokine secretion [26, 27]. It is therefore possible that while similar NFĸB dysfunction may
exist in HD T lymphocytes, a relatively reduced role of the pathway means compensatory
mechanisms are in place to prevent obvious phenotypic dysfunction. The mechanism of NFĸB
activation is also different in each cell type. NFĸB activation in myeloid cells takes place as a
result of LPS stimulation of the TLR4 receptor [28], whereas T lymphocytes are classically
stimulated via the T lymphocyte receptor [29]. While TLR4 is expressed by helper T lympho-
cytes, its exact function remains unclear, and has even been suggested to repress T lymphocyte
activation [30]. It has also been suggested that NFĸB has anti-inflammatory functions in naïve
CD4+ T lymphocytes, with overexpression of the p50 subunit of NFĸB leading to reduced tran-
scription of the signature Th1 cytokine IL-2 [31]. Taken together, these results suggest that the
lack of obvious phenotypic changes may be due to the altered and reduced role of NFĸB signal-
ling in helper T lymphocytes compared to myeloid cells.
Transcriptional dysregulation is a key feature of HD pathogenesis [20], with mHTT aggre-
gates thought to sequester transcription factors [21] in addition to mHTT fragments binding
directly to DNA [22]. However, the effect of mHTT is likely to vary between different signalling
pathways. Here we demonstrate that widespread changes in T lymphocyte related genes are
lacking in HD helper T lymphocytes in both the unstimulated and stimulated states. Key sig-
nalling molecules such as MAPK8 (JNK1) and JAK1/2 were unaffected in HD T lymphocytes,
supporting our hypothesis that alternative signalling pathways are able to compensate for
potential NFĸB pathway dysfunction. While the key Th2 transcription factor STAT6 was
found to be upregulated in stimulated HD cells, no changes were found in any related mole-
cules. Indeed, it has been shown that JAK/STAT signalling is not significantly affected in HD
myeloid cells [32], making it likely that this result (fold change 1.23) does not have a great deal
of functional significance. Furthermore, the transcript levels of pro-inflammatory cytokines
such as IL-6 and TNFα are unchanged between HD and control cells. Interestingly, we have
previously shown that IL-10 mRNA is significantly upregulated in HD myeloid cells compared
to controls [10], but no such difference exists in helper T lymphocytes. These results support
our conclusion that mHTT does not affect the intrinsic phenotype of HD helper T lymphocytes
in the same way it affects HDmyeloid cells.
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It is important to note that these results do not exclude the possibility of differences in T
lymphocyte function in vivo, as excessive stimulation from hyper-reactive myeloid cells could
provoke increased cytokine release from T lymphocytes through feedback loops. This is one
potential explanation for the increased IL-4 levels seen in manifest HD plasma [6], although it
has also been suggested that increased secretion of this anti-inflammatory cytokine may be a
compensatory response to chronic inflammation [33]. This conclusion is supported by the
increased IL-4 levels only being seen in the later stages of the disease. However, such a compli-
cated functional experiment is beyond the scope of this study.
Here we have shown that the intrinsic phenotype of helper T lymphocytes is not signifi-
cantly affected by the presence of mHTT. This advances our understanding of HD as a disease
of the whole body, and supports our previous work suggesting that hyper-reactive monocytes
and macrophages are the most likely source of peripheral immune dysfunction in HD [10].
This has important implications for future novel therapies aimed at modulating the peripheral
immune system, as it shows that only targeting certain cell types is likely to be beneficial. Fur-
thermore, it demonstrates the value of a systematic approach to investigating the function of
different cell types in HD, as the phenotypic effects of mHTT are clearly dependent on the cel-
lular environment and the relative contributions of the pathways it interacts with.
Supporting Information
S1 Fig. Gating strategy for T lymphocyte subset analysis. After gating on live cells using a
FSC/SSC gate, a CD3 vs. FSC plot was used to determine the percentage of CD3+ T lympho-
cytes. Within the CD3+ population, the percentages of CD4+ helper T lymphocytes and CD8+
cytotoxic T lymphocytes were determined, before the percentages of CXCR3+ Th1 and CCR4
+
Th2 lymphocytes within the CD4
+ population were determined. Activation levels of T lympho-
cytes based on CD62Llow expression were also determined.
(TIF)
S2 Fig. Gating strategy for T lymphocyte proliferation analysis. After gating on live cells
using a FSC/SSC gate, non-viable cells were excluded using Fixable Viability Dye 660. A CD3
vs. FSC plot was then used to determine the percentage of CD3+ T lymphocytes. Within the
CD3+ population, the percentages of CD4+ helper T lymphocytes and CD8+ cytotoxic T lym-
phocytes were determined before a histogram was used to analyse the CFSE fluorescence pro-
file of each cell population. The fraction diluted statistic was calculated by creating a univariate
gate below the undivided peak, while all other proliferation statistics were calculated using the
proliferation analysis tool included in the FlowJo software.
(TIF)
S3 Fig. Cytokine production by unstimulated CD4+ helper T lymphocytes is not affected in
HD vs. control. CD4+ helper T lymphocytes were isolated from HD and control peripheral
blood using magnetic cell sorting and seeded without stimulation. Supernatants were collected
after 48 h and cytokine profiling was carried out. No significant differences were seen in the
detectable levels of any cytokines produced by HD and control CD4+ T lymphocytes after nor-
malisation to total protein levels. Data show mean concentrations ± SEM. Statistical analysis
was carried out using two-tailed unpaired student’s t tests.
(TIF)
S1 Table. Age andHTT CAG repeat lengths of subjects participating in the study. The
cohort used for each experiment is listed separately.
(DOCX)
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S2 Table. Directly conjugated antibodies used for flow cytometry.
(DOCX)
S3 Table. Analysis of T lymphocyte proliferation data using the percentage divided statis-
tic. Percentage divided is calculated as the percentage of cells from the initial culture which
divided at least once. HD n = 8, control n = 9. Data shown as mean ± SEM.
(DOCX)
S4 Table. Analysis of T lymphocyte proliferation data using the proliferation index statis-
tic. Proliferation index is calculated as the average number of divisions undergone by the divid-
ing cells only. HD n = 8, control n = 9. Data shown as mean ± SEM.
(DOCX)
S5 Table. Analysis of T lymphocyte proliferation data using the division index statistic.
Division index is calculated as the average number of divisions undergone by all cells in culture.
HD n = 8, control n = 9. Data shown as mean ± SEM.
(DOCX)
S6 Table. Analysis of T lymphocyte proliferation data using the fraction diluted statistic.
Fraction diluted is calculated as the percentage of cells in the final culture which have divided
at least once. HD n = 8, control n = 9. Data shown as mean ± SEM.
(DOCX)
S7 Table. Complete list of expression changes observed in unstimulated HD helper T lym-
phocytes compared to controls. Data presented as fold change calculated from ΔΔ-CT values,
unpaired two-tailed t-test used as statistical method.
(DOCX)
S8 Table. Complete list of expression changes observed in stimulated HD helper T lympho-
cytes compared to controls. Data presented as fold change calculated from ΔΔ-CT values,
unpaired two-tailed t-test used as statistical method.
(DOCX)
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